Ann: Appendix 4C - quarterly, page-5

Pretty happy with the result, coming in pretty much as expected. Here's my figures I put out there 4 weeks ago.

"End of Financial year update next Friday(26th) presumably, then the Quarterly at the end of July and the Annual Report(appendix 4E) at the end of August.
Overall sales for Admedus was $7.8m, up from $7.4m(July 2014) Total income from tax rebates and commercialisation grants of $10.4m.
Initial sales into the US just began, and 12 centres were on board in Europe.
Receipts for the quarter to June 30, 2014 was $1,982,000.
Cash was $19,853,000
Total operating and investing cashflows was -$10,915,000

Total sales for this Financial year I'm predicting will be $9,100,000, up from $7.4m PCP
$2.8m for the quarter ending June 30
A R&D rebate could add another $2.5m
The loss will be around $21-$22m
Last quarter it was up to $15,698,000
Cash on hand should be $20-$21m

I try to be as accurate as possible off the top of my head with the loss and cash figures and go conservative with the centre numbers and sales

I tipped 80 centres for this quarter so 80+ is an outstanding result and just off being tripled by the company's own estimates as per their End of Financial Year update on the 26/06/2014.

The expenses have no doubt been justified imo and shows the skill of the board."